Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Type of study
Language
Publication year range
1.
J Diabetes ; 14(10): 658-669, 2022 Oct.
Article in English | MEDLINE | ID: mdl-36117320

ABSTRACT

Metformin is a hypoglycemic drug widely used in the treatment of type 2 diabetes. It has been proven to have analgesic and neuroprotective effects. Metformin can reverse pain in rodents, such as diabetic neuropathic pain, neuropathic pain caused by chemotherapy drugs, inflammatory pain and pain caused by surgical incision. In clinical use, however, metformin is associated with reduced plasma vitamin B12 levels, which can further neuropathy. In rodent diabetes models, metformin plays a neuroprotective and analgesic role by activating adenosine monophosphate-activated protein kinase, clearing methylgloxal, reducing insulin resistance, and neuroinflammation. This paper also summarized the neurological adverse reactions of metformin in diabetic patients. In addition, whether metformin has sexual dimorphism needs further study.


Subject(s)
Diabetes Mellitus, Type 2 , Diabetic Neuropathies , Metformin , Neuroprotective Agents , Adenosine Monophosphate/metabolism , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/drug therapy , Diabetic Neuropathies/drug therapy , Diabetic Neuropathies/etiology , Humans , Hypoglycemic Agents/therapeutic use , Metformin/therapeutic use , Neuroprotective Agents/therapeutic use , Pain , Protein Kinases/metabolism , Vitamin B 12
SELECTION OF CITATIONS
SEARCH DETAIL